Suppr超能文献

镰状细胞危象中髓系-淋巴系起始细胞和重症联合免疫缺陷重建细胞的自发循环

Spontaneous circulation of myeloid-lymphoid-initiating cells and SCID-repopulating cells in sickle cell crisis.

作者信息

Lamming Christopher E D, Augustin Lance, Blackstad Mark, Lund Troy C, Hebbel Robert P, Verfaillie Catherine M

机构信息

Stem Cell Institute, Division of Gastroenterology, University of Minnesota, Minneapolis, Minnesota 55455, USA.

出版信息

J Clin Invest. 2003 Mar;111(6):811-9. doi: 10.1172/JCI15956.

Abstract

The only curative therapy for sickle cell disease (SCD) is allogeneic hematopoietic stem cell (HSC) transplantation. Gene therapy approaches for autologous HSC transplantation are being developed. Although earlier engraftment is seen when cells from GCSF-mobilized blood are transplanted than when bone marrow is transplanted, administration of GCSF to patients with SCD can cause significant morbidity. We tested whether primitive hematopoietic progenitors are spontaneously mobilized in the blood of patients with SCD during acute crisis (AC-SCD patients). The frequency of myeloid-lymphoid-initiating cells (ML-ICs) and SCID-repopulating cells (SRCs) was significantly higher in blood from AC-SCD patients than in blood from patients with steady-state SCD or from normal donors. The presence of SRCs in peripheral blood was not associated with detection of long-term culture-initiating cells, consistent with the notion that SRCs are more primitive than long-term culture-initiating cells. As ML-ICs and SRCs were both detected in blood of AC-SCD patients only, these assays may both measure primitive progenitors. The frequency of ML-ICs also correlated with increases in stem cell factor, GCSF, and IL-8 levels in AC-SCD compared with steady-state SCD and normal-donor sera. Because significant numbers of ML-ICs and SRCs are mobilized in the blood without exogenous cytokine treatment during acute crisis of SCD, collection of peripheral blood progenitors during crisis may yield a source of autologous HSCs suitable for ex-vivo correction by gene therapy approaches and subsequent transplantation.

摘要

镰状细胞病(SCD)唯一的治愈性疗法是异基因造血干细胞(HSC)移植。目前正在开发用于自体HSC移植的基因治疗方法。虽然与骨髓移植相比,移植来自粒细胞集落刺激因子(GCSF)动员血液中的细胞时植入更早,但给SCD患者使用GCSF会导致显著的发病率。我们测试了在急性危机期间SCD患者(AC-SCD患者)血液中原始造血祖细胞是否会自发动员。AC-SCD患者血液中髓系-淋巴系起始细胞(ML-IC)和重症联合免疫缺陷(SCID)重建造血细胞(SRC)的频率显著高于稳态SCD患者或正常供体血液中的频率。外周血中SRC的存在与长期培养起始细胞的检测无关,这与SRC比长期培养起始细胞更原始的观点一致。由于仅在AC-SCD患者的血液中检测到ML-IC和SRC,这些检测可能都能检测原始祖细胞。与稳态SCD和正常供体血清相比,AC-SCD中ML-IC的频率也与干细胞因子、GCSF和白细胞介素-8水平的升高相关。由于在SCD急性危机期间无需外源性细胞因子治疗,血液中就有大量ML-IC和SRC被动员,在危机期间收集外周血祖细胞可能会产生适合通过基因治疗方法进行体外校正并随后移植的自体HSC来源。

相似文献

引用本文的文献

本文引用的文献

8
Bone marrow transplantation in sickle cell anemia.镰状细胞贫血的骨髓移植
Curr Opin Oncol. 2001 Mar;13(2):85-90. doi: 10.1097/00001622-200103000-00001.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验